Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Set to Delist Genomic Solutions; Company to Appeal

NEW YORK, Sept. 18 - Genomic Solutions today said it will appeal a decision by the Nasdaq exchange to delist the company's stock.


The Nasdaq informed Genomic Solutions of its intent on Sept. 12 after the company failed over 90 calendar days to raise its share price above $1. The letter followed a warning the exchange sent the company in mid-June for failing to keep its share price above $1 for 30 consecutive trading days.


Genomics solutions, which received the delisting notification on Sept. 12 but disclosed the news after the markets closed today, said it has requested a hearing before the Nasdaq Listing Qualifications Panel. A date for the appeal has not yet been set.


Steven Richvalsky, Genomic Solutions' CFO, was unavailable for comment. A company statement stressed that an appeal does not guarantee it will continue listing on the exchange.


Shares in Genomic Solutions closed down $.24 to $.47 today.


The company is set to be acquired by Harvard Bioscience in the fourth quarter. It was not immediately clear whether a delisting would affect the planned acquisition.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.